Avapritinib

Evidence Level: L5 Predicted Indications: 51

Quick Overview

Item Value
Drug Name Avapritinib
DrugBank ID DB15233
Brand Names (EU) Ayvakyt
Evidence Level L5
Predicted Indications 51
Top Prediction Score 99.92%

Approved Indication (EMA)

Unresectable or metastatic gastrointestinal stromal tumour (GIST) AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. Advanced systemic mastocytosis (AdvSM) AYVAKYT is indicated as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haemato

Predicted New Indications

TxGNN model predictions for potential drug repurposing:

Rank Indication Score Source
1 axial spondylometaphyseal dysplasia 99.92% DL
2 bilateral parasagittal parieto-occipital polymicrogyria 99.92% DL
3 amyotrophic lateral sclerosis 99.92% DL
4 trichomegaly-retina pigmentary degeneration-dwarfism syndrome 99.92% DL
5 amyotrophic lateral sclerosis, susceptibility to 99.91% DL
6 amyotrohpic lateral sclerosis type 22 99.91% DL
7 lower motor neuron syndrome with late-adult onset 99.91% DL
8 lethal arthrogryposis-anterior horn cell disease syndrome 99.90% DL
9 monomelic amyotrophy 99.89% DL
10 Mills syndrome 99.89% DL
11 autosomal dominant mitochondrial myopathy with exercise intolerance 99.89% DL
12 familial generalized lentiginosis 99.87% DL
13 rhabdoid tumor 99.86% DL
14 gastrocutaneous syndrome 99.86% DL
15 acromelanosis 99.84% DL
16 congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome 99.84% DL
17 Moynahan syndrome 99.84% DL
18 osteopathia striata-pigmentary dermopathy-white forelock syndrome 99.83% DL
19 leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome 99.82% DL
20 peripheral nerve schwannoma 99.80% DL

Showing top 20 of 51 predictions.

About TxGNN Predictions

Prediction Sources

Source Description
KG Knowledge Graph - Network topology-based associations
DL Deep Learning - Neural network score prediction

Evidence Levels

Level Definition
L1 Multiple Phase 3 RCTs / Systematic Reviews
L2 Single RCT or multiple Phase 2 trials
L3 Observational studies / Large case series
L4 Preclinical / Mechanistic / Case reports
L5 AI prediction only (current)

Clinical Validation Needed

Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.

Next Steps for Validation

  1. Literature Review: Search PubMed for existing evidence
  2. Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
  3. Mechanistic Analysis: Evaluate biological plausibility
  4. Preclinical Studies: Conduct in vitro/in vivo validation
  5. Clinical Trials: Design and conduct human studies

Data Access

Citation

If using this data, please cite:

@article{huang2023txgnn,
  title={A foundation model for clinician-centered drug repurposing},
  author={Huang, Kexin and others},
  journal={Nature Medicine},
  year={2023},
  doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.

Copyright © 2026 EuTxGNN Project. For research purposes only. Not medical advice.